A Phase I Dose Escalation Study on the Tolerability and Activity of TriN 2755 in Patients With Advanced Solid Tumors and Sarcomas Using Two Different Dosage Regimens
This is an open-label, parallel-group, two-center, safety, activity and pharmacokinetic study of TriN 2755 given at increasing dose levels as intravenous infusions administered over 4 hours. The study is divided into two parts: Part I a dose escalation phase and Part II an extension phase.
100 Clinical Results associated with Trin Therapeutics GmbH
0 Patents (Medical) associated with Trin Therapeutics GmbH
100 Deals associated with Trin Therapeutics GmbH
100 Translational Medicine associated with Trin Therapeutics GmbH